Clinical trial
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer's Disease
NCT06335173 is registered in ClinicalTrials.gov with Acumen Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer's Disease
- Lead sponsor
- Acumen Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 29, 2024
- Completion date
- October 31, 2026
- Enrollment
- 542 (actual)
- Sites
- 68
Conditions
As the registry lists them; a condition with its own page is linked.